Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model by Coudeville, Laurent et al.
RESEARCH ARTICLE Open Access
Relationship between haemagglutination-
inhibiting antibody titres and clinical protection
against influenza: development and application
of a bayesian random-effects model
Laurent Coudeville
1*, Fabrice Bailleux
1, Benjamin Riche
2, Françoise Megas
1, Philippe Andre
1, René Ecochard
2
Abstract
Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay
are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to
correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts
have been made to further quantify the association between HI titre and protective efficacy.
Methods: We present a model, using a meta-analytical approach, that estimates the level of clinical protection
against influenza at any HI titre level. Source data were derived from a systematic literature review that identified
15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information
on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using
Bayesian inference with a consideration of random effects and censorship in the available information.
Results: A significant and positive relationship between HI titre and clinical protection against influenza was
observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or
B) and the vaccination status of the individuals.
Conclusion: Although limitations in the data used should not be overlooked, the relationship derived in this
analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data
are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based
on their immunological profile.
Background
Influenza is a common, highly contagious viral respira-
tory disease. Annually it affects 5 to 15% of the world’s
population, causing considerable morbidity and mortal-
ity in all age groups [1]. Influenza vaccines have been
available for more than half a century. For optimal effi-
cacy, vaccine strain compositions are updated regularly
to counter “antigenic drift” that occurs progressively
from season to season as a consequence of immune
selection, so that the vaccine antigens are as close as
possible to the circulating wild-type antigens. Current
inactivated vaccines comprise preparations of virus
from two subtypes of influenza A (H1N1 and H3N2)
and one of influenza B. Purification of these trivalent
vaccines leaves mainly viral haemagglutinin (HA) and
neuraminidase (NA) glycoproteins. The haemagglutina-
tion-inhibiting (HI) antibodies generated in response
t os t i m u l a t i o nb ya ne x p o s u r et oH Ap r e v e n t si n f e c t i o n
by disrupting the binding of the virus to host recep-
tors. The concentration of HI antibodies in the blood
(HI titre) is measured using a specific immunological
assay [2].
Despite the extensive use of the HI assay in the annual
approval process of inactivated vaccines [3,4] and in the
evaluation of new seasonal or pandemic influenza vac-
cines, limited attempts have been made to use HI as a
means to predict influenza vaccine efficacy. Based nota-
bly on the observations made in a seminal paper by * Correspondence: laurent.coudeville@sanofipasteur.com
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to be associated with a 50% reduction in the risk of ill-
ness in a susceptible population [6], and can be referred
to as the 50% protective titre (50% PT).
Recently, Gilbert et al. [7] used logistic regression to
analyze the relationship between HI titre and vaccine
efficacy but only as an illustrative example with data
coming from one of the first clinical trials ever per-
formed [8].
Better understanding of the relationship between HI
titre and protection against illness may help evaluate
vaccine efficacy when only immunological data are avail-
able. Pandemic vaccines offer a good illustration of cir-
cumstances in which an immune correlate is potentially
useful for the assessment of vaccine efficacy [9]. More
generally speaking, correlates of protection are valuable
in any situation where practical issues or resource lim-
itations prevent the direct estimation of vaccine efficacy.
Beyond the specific case of influenza, statistical valida-
tion of surrogate endpoints has generated extensive lit-
erature [10-13]. Recently, Qin et al [14] developed a
framework for the identification of different levels of
correlates of protection adapted to the context of vacci-
nation. Several applications of this methodology exist
for drugs in the literature (see e.g. Molenberghs et al
[15]), but only a few can be found for vaccines using
either the results of a single clinical trial [7,16,17] or
simulated data [18].
Here we describe the development of a model, using a
meta-analytical approach, that relates protection against
laboratory-confirmed influenza to HI titre.
The methodological problems raised by the develop-
ment of this model can be divided in three categories.
The first category is related to the nature of the relation
between HI titre and protection against influenza. This
relation is unlikely to be of linear form and the preven-
tive role of HI antibodies must be separated from other
factors that influence the occurrence of influenza illness.
The second stems from the geographic and temporal
variation that affects not only virus circulation but also
possibly the level of protection conferred by HI titres.
Assessing such variations requires the use of a meta-
analytical approach with datasets collected over time in
vaccinated and unvaccinated populations. We therefore
considered a nonlinear hierarchical model with random
effects associated with all parameters to be estimated.
The third type of methodological problem is directly
l i n k e dt ot h en a t u r eo fd a t aa v a i l a b l et op e r f o r mt h i s
estimation. They were collected from articles published
in the medical literature and in which data are pre-
sented for a limited number of HI titre intervals. The
model developed therefore accounts for this interval-
censorship.
Methods
A model for estimating the relation between HI titre and
protection against influenza
A simple model for one study, no censorship and no
covariates
Influenza illness is the result of a complex process invol-
ving the risk of being in contact with an infectious indi-
vidual, the risk that this contact leads to infection and
finally the risk that infection results in illness. Our
objective is not to model this whole process in detail
but to focus on the protection afforded to an individual
by the level of humoral HI antibodies.
The model starts with a baseline risk (0 ≤ l ≤ 1) that
an individual develops influenza in absence of any HI-
related protection. To estimate the risk that an indivi-
dual develops influenza (P(yj = 1)) in presence of HI
antibodies, this baseline risk is combined with a function
defining the contribution of HI titre to the individual’s
protection (0 ≤ π (Tj, θ) ≤ 1, where Tj is the HI titre
and θ is the associated vector of parameters). More
specifically:
PY T T jj j (, , ) ( ( , ) )   11     (1)
To fully characterize this estimation, the functional
form associated with π (Tj, θ), hereafter referred to as
the HI-protection curve, needs to be specified. π (Tj, θ)
will be a flexible and smooth increasing function. In
accordance with Dunning [16] it is specified as a two-
parameter inverse logit function (θ ={a, b}) applied to
log-transformed HI titre values. The original model is
then further modified to make its parameters more
directly interpretable, leading to the following equation:
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The parameter a is closely linked to the 50% protec-
tive titre (50% PT) first identified by Hobson et al [5]:
∀θ, Tj = e
a ⇒π (Tj, θ) = 0.5. The parameter a can there-
fore be interpreted as a location parameter for the HI
protection curve.
The parameter b is also easily interpretable since it is
directly related to the slope of π (Tj, θ)f o r
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4 , i.e. it describes the
steepness of the HI protection curve.
A random-effects model with uncensored data with
covariates
The inclusion of multiple datasets (i = 1, ..., I) enables to
account for the heterogeneity likely to impact the HI
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Page 2 of 11protection curve. This was done using a hierarchical
model, considering random effects for the parameters of
the curve (ai, bi). The datasets considered for these ran-
dom effects correspond to observations made for one
virus strain in one study.
Part of this heterogeneity may be explained by rele-
vant covariates. We tested the impact of several covari-
ates by adding in some models a vector of binary
variables Xi with associated parameters ac, bc.T h i s
representation limits the analysis to covariates whose
values are common to all subjects of a given dataset and
are consistent with the type of data considered.
Finally, the baseline risks li, which are unrelated to
the HI protection curve, will be treated as independent
dataset-specific parameters. No assumption was there-
fore made on the variation of li across studies. Similarly
to random effects, we consider baseline risks to be spe-
cific to datasets corresponding to observations made for
one influenza strain in a study.
The probability to be estimated becomes
P Y TX TX i
e ic T
ij ij ij i i i ij i i (, , , ) ( ( , , ) )
log(
  
  
11
1
   

 i ij i c )   (3)
Where θi ={ ai, bi, ac, bc}.
A random-effects model with interval-censored data with
covariates
Censorship does not modify the structure of the ran-
dom-effects model but rather necessitates an additional
stage for its estimation. In a Bayesian framework, cen-
sorship can be accounted for using data augmentation
techniques [19]. The basic idea is to consider the
unknown Tij values as latent variables and to use sam-
pling to impute their possible values given their underly-
ing distribution and the interval to which they are
known to belong TT ij ij
 


 , . With this approach, Tij are
in fact treated as additional parameters. We considered
here that the log-transformed HI titres are normally dis-
tributed (with mean μi a n ds t a n d a r dd e v i a t i o nsi)a n d
specific to each dataset considered in the analysis. Pro-
vided that censorship is non-informative, the relation-
ship between HI titres and clinical protection continues
to be estimated using equation (3).
Estimation methods
The nature of the model considered led us to adopt a
Bayesian approach to perform the estimation of its para-
meters. Markov Chain Monte Carlo (MCMC) methods
were implemented using the Bayesian software package
WinBUGS [20]. The corresponding directed acyclic
graph is presented Figure 1. Posterior summary statistics
were based on 3 Markov chains of 20,000 lengths after a
burn-in period of 20,000 iterations. Convergence was
assessed using Gelman-Rubin statistics [21] as well as
the iteration history and kernel densities.
We assumed the two random parameters of the HI
protection curve to be normally distributed
(       ii NN ~l o g ( , ), ~ ( , )
22 ). For dataset-spe-
cific and other parameters, we selected the following
non-informative prior distributions:
 
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Our choice of non-informative priors is quite usual. It
is however worth mentioning that for the baseline risks
li, we specifically considered Jeffreys prior for the Beta
distribution which can be regarded as less informative
than the alternative choice li ~ Beta(1,1) (see e.g. Gupta
and Nadarajah [22]).
The comparison of the estimation of the HI protection
curve obtained with the different models tested was
mainly performed using the Deviance Information Cri-
terion (DIC) [23]. This criterion, an Akaike-like criterion
for Bayesian models, assesses the goodness-of-fit of a
model using posterior mean deviance. To compare mod-
els with and without covariates, we also used the 95%
credible interval of the parameters associated with
covariates.
Data
To estimate HI-related protection, we reviewed the lit-
erature to identify datasets combining information on
HI antibody titre and the occurrence of influenza. Rele-
vant publications from 1945 to 2006 were identified in
the Medline and Embase databases using the search
terms: influenza, immune correlate, protection, vaccina-
tion, vaccine, immunogenicity, protective efficacy, sero-
logical surrogate.
We identified 36 articles, 21 of which were excluded
based on inclusion of non-target populations (children in
9 studies; pregnant women in 1 study); insufficient data
to allow quantification of the link between HI titre and
influenza protection (6 studies); vaccination using live
vaccines (3 studies); previously reported data (2 articles).
Fifteen articles were thus retained: 6 challenge studies,
5 clinical trials and 4 cohort studies (Table 1). In chal-
lenge studies, healthy adult volunteers were randomised
to receive vaccine or placebo and then were exposed to
a fixed dose of influenza virus after a pre-challenge
serum HI titre assessment. In clinical trials, participants
were randomized to receive vaccine or placebo before
the influenza season, and had at least a pre-season
serum HI titre assessment. In cohort studies, all the par-
ticipants included in the cohort had at least a pre-season
serum HI titre assessment, performed after immuniza-
tion for vaccinated participants. In all clinical trials and
cohort studies, the occurrence of influenza was observed
during the influenza season following the HI titre
assessment. Most study subjects were adults younger
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Page 3 of 11than 60 years, and only one study included elderly
adults (60+ years) [24].
Several studies reported data for both vaccinated and
non-vaccinated populations and HI titres corresponding
to different vaccine strains. We split this information
into different datasets to consider homogeneous groups
of subjects in terms of HI titre information and vaccina-
tion status. Thus, the 15 articles provided 37 datasets
presented Table 1 for a total of 5889 observations and
1304 influenza cases. All except 39 influenza cases in
one study [24] were laboratory confirmed using paired
serology (four fold change) or virus isolation.
These data enabled us to test the effect of circulating
strain (A or B), vaccine exposure (yes or no), study
design (clinical trial, challenge study or cohort study)
and diagnostic method (laboratory-confirmed clinical
diagnosis, serological diagnosis and clinical diagnosis).
HI titres are measured using a two-fold serial dilution
assay, which determines the highest dilution of serum
which still inhibits haemagglutination [2]. So while the
concentration of HI antibodies can be considered to be
a continuous variable, and will be treated as such in our
analysis, the assay only provide a limited number of pos-
sible results, creating the first level of censorship. A sec-
ond level of censorship results from how the data are
published. In most of the cases, data are reported for a
limited number of HI titre intervals and not for each
possible result of the HI assay.
Results
Gelman-Rubin statistics and kernel densities (Figure 2)
confirm that the markov chains and the burn-in period
are sufficiently long for the posterior statistics to be
meaningful. The results presented Table 2 show a
ij T ij T
ij Yij Y
ij Tij T
j=1,Ni
i i i i
i X ij
i i
i=1,I
i i
i i
c c
c c
Figure 1 Directed acyclic graph of the interval-censored model with covariates. Square boxes represent fixed quantities, white circles
stochastic nodes, grey circles logical nodes, solid arrows stochastic dependencies and dashed arrows deterministic dependencies. Bold lines
corresponds to nodes associated with data.
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t h eo c c u r r e n c eo fi n f l u e n z a :b is significantly different
from 0 and positive whatever the model considered.
These results are reinforced by the overall good fit to
the data illustrated Figure 3 for the ALL model (all
available data included and no covariate).
The impact of covariates related to vaccination status
and virus strain are important for the interpretation of
the HI protection curve. In both cases, their impact is
not significant: DIC does not decrease or even increase
when {ac, bc} are added to the model and none of these
parameters significantly differ from 0. The same curve
therefore seems to apply regardless of the type of virus
strain considered and regardless of the vaccination sta-
tus of the subjects. This latter result is of particular
importance as the absence of significant differences
between vaccinated and non vaccinated subjects corre-
sponds to a condition set by Prentice [10] for defining
an accurate surrogate endpoint.
We also estimated the HI protection curve considering
only the data reported by Hobson et al [5] (HOB
model). The 50% level of protection is obtained with
this model for a log-transformed HI titre is 3.38 [95%
CI:1.5;5.2] corresponding to 1:29 in the natural scale,
which is consistent with the 50% protection titre identi-
fied by Hobson and his co-workers (1:18-1:36) but
remains higher to that obtained in the ALL model (1:17
in the natural scale). The credible interval is also much
wider in the HOB model [1:5;1:195] than in the ALL
model [1:10;1:29], which indirectly supports the use of a
meta-analytical approach to obtain more robust esti-
mates and to distinguish uncertainty from heterogeneity.
Table 1 Characteristics of studies included in the analyses
Author, year Design Vaccination status
£* Vaccine
strain
Number of HI titre
intervals
$
Drop-out
rate#
Vaccinated Unvaccinated Unknown
Bell et al., 1957 [32] Challenge 32 (14) - A 3 > 10%
Clark et al., 1983a [33] Challenge 49 (7) 23 (16) A 6 ≤ 10%
Clark et al., 1983b [34] Challenge 39 (6) 58 (23) A 5 ≤ 10%
Dowdle et al., 1973 [35] Trial 227 (90) A 4 ≤ 10%
Eaton and Meiklejohn, 1945 [36] Trial 94 (4) 145 (9) A(Olson) 5 ≤ 10%
94 (9) 145 (4) A(PR8)
94 (9) 145 (4) B
Evans, 1975 [37] Cohort 696 (262) - A 5 NA
346 (47) B
Farnik and Bruj, 1966 [38] Cohort - 248 (52) A 5 ≤ 10%
Fox et al., 1982 [39] Cohort - - 222 (13) A(H1N1) 4 ≤ 10%
343 (98) A(H3N2) 3
140 (28) B 3
Goodeve et al., 1983 [40] Challenge 97 (9) 23 (15) B 6 ≤ 10%
Greenberg, Couch and Kasel, 1974
[41]
Cohort - 212 (97) A 5 ≤ 10%
Hirota et al., 1997 [24] Trial 84 (4) 118 (9) A(H1N1) 3 ≤ 10%
84 (4) 118 (9) A(H3N2)
84 (4) 118 (9) B
Hobson et al., 1972 [5] Challenge 106 (20) A(Field Trial) 9 NA
345 (166) A(HK
Salisbury)
- - 119 (62) A(Pre-1968)
462 (135) B
Meiklejohn et al., 1952 [42] Trial - 101 (5) A 6 > 10%
Potter et al., 1977 [43] Challenge 134 (26) - A 6 ≤ 10%
Salk et al., 1945 [8] Trial 82 (2) 246 (21) A(Weiss) 10 > 10%
82 (2) 144 (12) A(PR8)
*: Number of observations (number of influenza cases)
$. Number of reported intervals on pre-season HI titres.
£ Vaccination performed just before exposure
# Number of subjects analyzed/Number of subjects included in the analysis
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22 , reported in Table 2
provide insight on the importance of the heterogeneity
of the HI protection curve across studies. Significant
variations can be observed: the 25% percentile associated
with the variation of the 50% PT from one study to
another can be calculated to correspond to a HI titre of
1:10 and the 75% percentile to a HI titre of 1:30. Simi-
larly, the steepness of the HI protection curve, as mea-
sured by b, ranges from 1.05 to 1.55.
Finally, we tested covariates corresponding to the con-
ditions in which the observations on influenza were col-
lected (Table 3): study design (DES model) and
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Figure 2 Gelman-Rubin diagnostic plot (a) and kernel densities (b) (ALL model). GR plot: blue corresponds to within-chain variability, green
to between chain variability and red to their ratio.
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Page 6 of 11diagnostic method (DIAG model). None of these covari-
ates improved data fit as measured by the DIC criterion
or the significance of the corresponding parameters.
Overall, our results support the conclusion that the
best representation of the relationship between HI titres
and protection against influenza is obtained when com-
bining all available data without any covariate (ALL
model). The corresponding HI protection curve is pre-
sented Figure 4.
Discussion
Although the association between serum HI antibody
titre and protection against clinical influenza is well
established [25,26], the precise nature of the relationship
Table 2 Impact of vaccination status and vaccine strain on the estimation of HI-related protection
Model name
$ ALL STRAIN ALL_V VAC HOB
Number of subjects 5899 5899 4162 4162 1032
Number of flu cases 1304 1304 782 782 383
Parameter Estimates*
μa [95% CI] 2.844 [2.25;3.36] 2.964 [2.27;3.53] 2.344 [1.49;3.14] 2.615 [1.63;3.56] 3.385 [1.53;5.27]
sa [95% CI] 0.845 [0.44;1.41] 0.85 [0.42;1.43] 0.944 [0.33;1.69] 1.06 [0.37;2] 1.415 [0.28;5.37]
μb [95% CI] 1.299 [1;1.69] 1.404 [1.04;1.91] 1.061 [0.77;1.48] 1.205 [0.81;1.69] 2.102 [-0.27;6.36]
sb [95% CI] 0.376 [0.1;0.76] 0.386 [0.07;0.81] 0.275 [0.05;0.66] 0.206 [0.01;0.62] 2.102 [0.19;11.93]
ac [95% CI] -0.467 [-1.72;0.81] -1.04 [-2.93;0.7]
bc [95% CI] -0.305 [-1.06;0.42] -0.377 [-0.98;0.23]
E[li] [95% CI] 0.482 [0.41;0.57] 0.481 [0.41;0.57] 0.497 [0.39;0.61] 0.531 [0.41;0.67] 0.726 [0.64;0.81]
E[μi] [95% CI] 3.116 [2.93;3.26] 3.117 [2.94;3.26] 3.129 [2.91;3.3] 3.13 [2.91;3.3] 3.157 [2.96;3.35]
E[si] [95% CI] 0.752 [0.69;0.82] 0.752 [0.69;0.82] 0.775 [0.71;0.85] 0.773 [0.71;0.85] 0.181 [0.16;0.21]
DIC 4667.0 4667.0 3074.0 3077.0 964.2
$. ALL: All datasets and no covariate, STRAIN: All datasets + 1 covariate for virus strain (reference category: type A virus), ALL_V: datasets with information on
vaccination status, VAC: datasets with information on vaccination status + 1 covariate for vaccination status (reference category: vaccinated), HOB: data reported
in Hobson et al. [5], no covariate
* Reported values for each parameter: posterior mean value and 95% credible interval
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Figure 3 Estimated (Y-axis) versus observed (X-axis) number of influenza cases for the 37 datasets considered in the analysis (ALL
model). Red corresponds to vaccinees, blue to non vaccines, grey to unknown status, circles to type A strain and triangles to type B.
Coudeville et al. BMC Medical Research Methodology 2010, 10:18
http://www.biomedcentral.com/1471-2288/10/18
Page 7 of 11Table 3 Impact of study design and diagnostic method on the estimation of HI-related protection
Model name
$ ALL DES DIAG DOR
Number of subjects 5899 5899 5899 3825
Number of flu cases 1304 1304 1304 612
Parameter Estimates*
μa [95% CI] 2.844 [2.25;3.36] 2.55 [1.49;3.44] 2.751 [1.79;3.75] 1.594 [1.78;6.39]
sa [95% CI] 0.845 [0.44;1.41] 0.936 [0.49;1.56] 0.905 [0.45;1.54] 0.956 [0.23;1.88]
μb [95% CI] 1.299 [1;1.69] 1.222 [0.8;1.77] 1.181 [0.75;1.72] -1.414 [3.59;1.37]
sb [95% CI] 0.376 [0.1;0.76] 0.412 [0.1;0.85] 0.428 [0.14;0.83] 0.211 [0.02;0.53]
Study design
a
aco [95% CI] 0.096 [1.23;1.44]
bco [95% CI] -0.021 [0.79;0.78]
ach [95% CI] 0.577 [0.82;1.97]
bch [95% CI] 0.241 [0.54;1.09]
Diagnosis
b
aser [95% CI] 0.091 [1.57;1.54]
bser [95% CI] 0.131 [0.58;0.89]
aili [95% CI] 0.07 [1.65;1.36]
bili [95% CI] 0.415 [0.52;1.45]
E[li] [95% CI] 0.482 [0.41;0.57] 0.5 [0.43;0.59] 0.491 [0.42;0.58] 0.505 [0.38;0.62]
E[μi] [95% CI] 3.116 [2.93;3.26] 3.115 [2.93;3.26] 3.112 [2.94;3.26] 3.168 [2.96;3.33]
E[si] [95% CI] 0.752 [0.69;0.82] 0.751 [0.69;0.82] 0.751 [0.69;0.82] 0.809 [0.74;0.89]
DIC 4667.0 4670.0 4669.0 2623.0
$. ALL: All datasets and no covariate, STRAIN: All datasets + 1 covariate for virus strain (reference category: type A virus), ALL_V: datasets with information on
vaccination status, VAC: datasets with information on vaccination status + 1 covariate for vaccination status (reference category: vaccinated), HOB: data reported
in Hobson et al. [5], no covariate
* Reported values for each parameter: posterior mean value and 95% credible interval
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Figure 4 Estimated probability of protection according to the level of HI titre. (All Model - Posterior Mean value and 95% credible interval).
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Page 8 of 11has drawn little attention. To address this, we developed
a model to provide an estimate of the level of protection
associated with any HI titre level for use to predict
influenza vaccine efficacy. Using HI data from multiple
studies, the model showed a positive and significant
relationship between immunogenicity and clinical pro-
tection. The relationship was notably found to be similar
for vaccinated and unvaccinated subjects which is in
accordance with Prentice criterion for a good surrogate
marker [10].
Our results challenge the usual approach of defining
protection based on the identification of a single thresh-
old. The slope of the protection curve in all of the mod-
els we tested favoured a progressive increase in
protection with increasing HI titre rather than a discrete
threshold that could be applied to each individual. The
incremental increase in clinical protection is however
particularly important at titres of up to 1:100 (which
includes the commonly used 1:40 threshold). Additional
benefits become marginal beyond 1:150, which concords
with the result derived by De Jong et al [25] who esti-
mated the median 90% PT for influenza vaccines to be
1:192. Our analysis therefore supports their conclusion
that developing influenza vaccines capable of reducing
t h en u m b e ro fp o o ro rl o wr e s p o n d e r sw o u l db ec l i n i -
cally beneficial.
The comparison between our reference case combin-
ing all available data (ALL model) and the model based
only on data reported by Hobson et al (HOB model)
provides a good illustration of the added value of the
analysis presented here. The results of HOB model are
consistent with the results reported in the original paper
in terms of 50%PT. Our model therefore does not con-
tradict previous results, but provides an enhanced repre-
sentation of the relationship between HI titre and
protection against influenza. In addition, the large confi-
dence intervals associated with HOB model highlights
the need to combine a large number of observations to
get an accurate representation of this relationship and
to account for the heterogeneity across studies. This is
precisely the added value of the meta-analytical
approach proposed here. This meta-analysis confirms
the existence of diversity likely to affect the interpreta-
tion of the results of a single study. This heterogeneity
can be explained both by the conditions in which the
subjects were exposed to influenza (e.g. time between
HI titre assessment and occurrence of influenza) or by
the design of the studies (e.g. laboratory methods).
It has to be mentioned that to simplify model specifi-
cation, we considered random effects capturing jointly
the heterogeineity across studies and across virus strains
in the same study. A more detailed representation
would have been possible notably to be able to consider
specifically these two levels of heterogeneity.
Overall, the different covariates considered did not
improve the fit to the data either measured by the DIC
criterion or by the significance of the corresponding
parameters. This result holds not only for vaccination
status but also for the type of viral strain, study design
and diagnostic method. This supports the idea of the
large applicability of the HI protection curve derived in
this analysis.
Some similarities can be found between our results for
HI assay and a statistical Surrogate of Protection (SoP)
defined by Qin et al [14] i.e. an immunological measure-
ment characterized by a relationship with the end point
of interest (in this case laboratory-confirmed influenza)
that is similar in vaccinees and non vaccinees. One
important point is that no attempt was made to estab-
lish a causal relationship but only to identify a statistical
link. it can for instance be argued that HI antibodies
only relate to the humoral immune response and there-
fore neglects the role played by cell-mediated immunity
[27]. However, the coexistence of different biological
mechanisms does not preclude the identification of a
statistical link with one specific measurement. It only
requires that this link is not improperly interpreted as
sufficient to explain the complex biological mechanisms
that trigger the protection against an infectious disease.
The main application of a surrogate of protection is
predicting vaccine efficacy. Although our analysis was at
this stage only focused on the derivation of an HI pro-
tection curve, this is clearly an important next step. The
HI protection curve can also be used for comparing vac-
cines characterized by different immunological profiles.
T h i sc a nb es e e na sa ni m p r o v e m e n to v e rt h eu s eo f
standard criteria such as seroprotection rates (i.e. per-
centage of subjects with a HI titre above the 1:40
threshold for protection). As pointed out by Nauta et al.
[28], such criteria may be misleading for this type of
comparison if the HI protection is better described as a
curve than using a threshold approach.
The reliability of our model depends directly on the
quality of data used for the estimation and calculation
phases. As we used published data, there were some
limitations that could not be overcome. The data were
acquired and published over a period of many years,
and the studies involved heterogeneous populations, dif-
ferent study designs, and in some cases inadequate or
no description of randomization procedures. The HI
test itself changed over time and is also subject to inter-
laboratory variability [29]. Other differences noted were:
vaccine composition and dosage, case definition, interval
between vaccination and antibody titration, assay
method. The selected datasets also had limited informa-
tion on the status of confounding factors such as pre-
vaccine antibody level titre, influenza vaccination his-
tory, prevalence of co-morbidities, nutritional
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could affect the immune system [30]. The lack of avail-
able information on baseline covariates such as previous
history of influenza disease or vaccination is another
limitation. Antigenic similarity between vaccine strains
and circulating strains, which vary with time, even dur-
ing a single season, plays a key role in vaccine efficacy.
While our use of results from 15 studies may have par-
tially overcome this heterogeneity, reported immuno-
genicity results generally correspond to vaccine strains
having a good match with circulating strains. This pro-
blem of matching is particularly critical for pandemic
vaccines, and the direct application of our results to vac-
cines developed in the context of pandemic prepared-
ness should be considered very cautiously. It is also
important to stress than H5N1 vaccines require a differ-
ent HI test than the one used for seasonal vaccines [31].
To further evaluate and establish this model, an
important development will be to perform a similar ana-
lysis using data that includes detailed information at the
individual level with a virological diagnosis of influenza
(most cases considered in this analysis were serologically
confirmed). The accuracy of such an analysis will how-
ever ultimately depend on the number of influenza
cases considered. We believe that our use of over 1000
influenza cases in establishing our model as well as the
consideration of study heterogeneity can be seen as the
major strength of the analysis performed.
Finally our analysis was exclusively focused on the case
of influenza. However, the question raised by the identifi-
cation of a good correlate of protection is applicable to
all vaccine-preventable diseases. Meta-analytical
approaches have been extensively used for validating sur-
rogate endpoints for therapeutic drugs [15], but the num-
ber of applications to vaccines remains very limited. The
approach used here, which relies on published informa-
tion to access a large number of cases (the “price to pay”
in terms of data quality being here censorship), could be
easily adapted to other vaccine-preventable diseases.
Conclusions
The model developed enables us to specify the relation-
ship between HI antibody titres and clinical protection
against influenza while accounting for heterogeneity
among studies. This relationship appears consistently
positive and similar irrespective of vaccination status or
viral strain and could be used to predict the efficacy of
inactivated influenza vaccines when only immunogeni-
city data are available.
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